TAK-659, a new Syk inhibitor, has recently shown antitumor activity in lymphoma xenograft models [32] and in diffuse large B cell lymphoma patients according to preliminary data from the first-in-human phase 1 clinical trial [33]. Here, SYK is linked to diffuse large B-cell lymphoma.